CONy 2023 | Thrombin generation as a predictor of outcomes in patients with intracerebral hemorrhage

The thrombin generation assay is a global hemostasis test providing information about the speed and amount of generated thrombin in plasma. Currently, it is mainly used in research, but it’s hoped to be broadly used in clinical practice in the future. Zsuzsa Bagoly, MD, PhD, University of Debrecen, Debrecen, Hungary, describes the clinical utility of the thrombin generation assay to predict outcomes in patients with non-traumatic intracerebral hemorrhage. The assay measures both the hyper- or hypocoagulability status, providing data on the thrombotic risk as well as the bleeding risk. Additionally, clinicians can follow the change in the coagulation status of patients who require reversal after anticoagulation. In COVID-19 patients, the assay was useful in identifying the optimal dose of thromboprophylaxis. This interview took place at the 17th World Congress on Controversies in Neurology (CONy) in Dubrovnik, Croatia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.